PrintShare

  • Home
  • >
  • News & Publications
  • >
  • News
  • >
  • Carter Ledyard Advises Client PainReform Ltd., an Israeli Biotechnology Company, in its Initial Public Offering on NASDAQ

News

Carter Ledyard Advises Client PainReform Ltd., an Israeli Biotechnology Company, in its Initial Public Offering on NASDAQ

Carter Ledyard client, PainReform Ltd., a clinical stage Israeli biotechnology company focused on the reformulation of established therapeutics, was advised by Carter Ledyard’s Steven J. Glusband and Guy Ben-Ami, together with Israeli firm Doron Tikotzky Kantor Gutman & Amit Gross, in its $20,000,000 initial public offering on September 1, 2020. PainReform’s proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.

Latest News

See all news items


© Copyright 2020 Carter Ledyard & Milburn LLP